Advanced Search

 

Study ID Status Title Patient Level Data
CRS105510 Completed A randomised, placebo-controlled, double-dummy, crossover design study to investigate the changes of fMRI BOLD activation induced by emotional activation paradigms following single doses of GSK561679 and lorazepam (comparator) in healthy subjects
CRS105511 Completed Placebo-Controlled, Randomized, Blinded, Double-Dummy, Crossover study to Investigate the Attenuation of ACTH Activation Induced by Metyrapone with a single dose of GSK561679 or Alprazolam in Healthy Volunteers
CRS-110300 Completed An open-label, single-dose, non-randomized, balanced design three-way cross-over study to examine the variability in absorption of GSK561679 using Gamma Scintigraphy, PillCamâ„¢ SB capsule and the acoustic vest in healthy males volunteers
CRV110734 Completed A study to evaluate the safety and tolerability of SK&F-105517-D in patients with chronic heart failure- An open-label study to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics of SK&F-105517-D in patients with chronic heart failure (Phase I/II study) Study Listed on ClinicalStudyDataRequest.com
CRZ107432 Completed A single blind, randomized, placebo controlled, crossover study to investigate the safety, tolerability and pharmacokinetics of single oral escalating doses of GSK586529 in healthy volunteers
CUC111342 Terminated An open label, 7-day repeat dose study to evaluate the pharmacodynamics of SB-656933-AAA in patients with Ulcerative Colitis. Study Listed on ClinicalStudyDataRequest.com
CXA10006 Completed A randomised, placebo-controlled, double-blind, parallel group study to investigate the effects of chronic dose oral GW406381 on pain and areas of hyperalgesia and allodynia in patients with peripheral nerve injury as a result of trauma or surgery.
CXA100754 Completed An open-label, non-randomised study of 20 mg GW406381 single dose pharmacokinetics in healthy subjects and in volunteers with moderate hepatic impairment
CXA30001 Completed A Pivotal Phase III, Single Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Dose-Ranging Study to Investigate the Efficacy and Safety of Single Oral Doses of 10mg, 25mg, 50mg and 70mg GW406381 and 550mg Naproxen Sodium in Subjects with Pain Following Third Molar Tooth Extraction
CXA30007 Completed A Phase III, 12-week, Multicentre, Double-Blind, Double-Dummy, Randomised, Placebo - and Active Comparator - Contolled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381 XXmg and YYmg Administered Orally Once Daily, in Adults with Osteoarthritis of the Knee
CXA30009 Completed A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg administered orally once daily, in Adults with Rheumatoid Arthritis
DAN106587 Completed A placebo controlled, single blind, randomised study investigating the safety, tolerability and Pharmacokinetics of repeated oral doses of GSK598809 in healthy male and female volunteers for 28 days.
DAN106589 Completed An open label positron emission tomography study in healthy male subjects to investigate brain Dopamine D3 occupancy kinetics, pharmacokinetics and safety of single oral doses of GSK598809, using [11C]-(+)-PHNO as PET ligand.
DAN106593 Completed A randomized, double-bind, placebo controlled, two-way cross-over study to assess the effects of a single dose of GSK598809, a Selective DRD3 Antagonist, in Modulating Nicotine Reward Study Listed on ClinicalStudyDataRequest.com
DAN107606 Completed A placebo-controlled, single-blind, randomised, human volunteer study investigating the tolerability and pharmacokinetics of escalating single oral doses of GSK598809 in smokers
DAN111282 Completed A placebo-controlled, single-blind, randomised, human volunteer study investigating the tolerability and pharmacokinetics of escalating single oral doses (75mg and above) of GSK598809 in otherwise healthy smokers
DAN111283 Completed An open label, randomised, single dose, three-way crossover study to investigate the relative bioavailability of a 100mg capsule compared to four 25mg GSK598809 capsules and the effect of food on the pharmacokinetics of the 100mg capsule in healthy male and female volunteers.
DB1111509 Completed A single centre, randomised, placebo-controlled, four-way cross over study to assess the safety, tolerability, pharmacodynamics and pharmacokinetics of single inhaled doses of GSK233705 and GW642444 as monotherapies and in combination in healthy subjects. Study Listed on ClinicalStudyDataRequest.com
DB1111581 Completed A multicenter, randomized, double-blind, placebo-controlled, parallel-group, 4-week study to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of repeat inhaled doses of the combination of GSK233705 and GW642444 administered once-daily in subjects with COPD Study Listed on ClinicalStudyDataRequest.com
DBU107640 Completed A First Time in Human, Blinded, Randomised, Placebo-Controlled, two-cohort Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Single Oral Escalating Doses of GSK618334 in Healthy Male Volunteers
DIX109177 Completed A Single-Blind, Randomized, Placebo Controlled, Ascending Single and Repeat Dose Study with Once Daily Dosing to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK376501 and to Evaluate Food Effects and the Relative Bioavailability of a Tablet Formulation Compared to the Powder for Reconstitution Formulation in Healthy Overweight and Obese Subjects (DIX109177)
DIX109980 Completed Phase I, Randomized, Open-Label, 3 Period Crossover Drug Interaction Study Between Simvastatin and GSK376501 in Healthy Subjects
DIX109981 Completed A Single-Blind, Randomized, Placebo-Controlled, Ascending Single Dose and Repeat Dose Study with Once Daily Dosing To Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK376501 in Healthy Overweight and Obese Subjects
DIX110434 Completed A Single-Center, Non-Randomized, Open-Label, Comparative Study to Assess the Utility of Novel Technologies and Biomarkers as Methods for Measuring Human Pharmacodynamic Response to 8 Weeks of Administration of Rosiglitazone Maleate 4mg BID in Healthy Normal or Overweight Controls, Healthy Obese Subjects and Subjects with Type 2 Diabetes Mellitus (T2DM) Study Listed on ClinicalStudyDataRequest.com
DIX110825 Completed A Single Center, Single Sequence, Open-Label, Repeat-Dose Study to Investigate the Effect of GSK376501 on Hepatic Cytochrome P450 Activity in Healthy Adult Subjects

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.